SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 14 – SEGMENT INFORMATION

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources, and assess performance.

The CODM examines, within each operational function the employee salaries including the bonus and share based compensation, clinical trials expenses within the research and development operations and certain other expenses.

The following table summarizes the Company’s segment revenue, significant segment expenses, and segment loss.

	Year ended December 31,
	2024			2023
Revenues		7,009			6,205
Cost of Revenues:
Material and Labor		4,698			3,807
Other cost of revenues		805			591
Total Cost of Revenues		5,503			4,398
Research and development (R&D)
Payroll and Benefits		2,858			1,916
Share based compensation		2,412			649
Clinical trials		3,815			3,300
Other R&D		4,549			2,116
Total Research and development		13,634			7,981
Selling and marketing (S&M)
Payroll and Benefits		3,769			2,508
Share based compensation		1,025			416
Other S&M		1,275			941
Total Selling and marketing		6,069			3,865
General and administrative (G&A)
Payroll and Benefits		4,221			3,344
Share based compensation		6,445			3,332
Other G&A		4,640			4,428
Total General and administrative		15,306			11,104
Financial Income, net;		1,557			1,292
Tax Expenses		59			65
Segment net Loss		(32,005	)		(19,916	)